357 Results

FDA approves Tecentriq, chemotherapy and epotoside to treat small cell lung cancer

 Added 1 day ago

Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide...

Phase III KEYNOTE-407 trial of Keytruda in combination with chemotherapy leads to first line EU approval for NSCLC

 Added 6 days ago

First line EU approval is based on data from the Phase III KEYNOTE-407 trial which demonstrated that Keytruda in combination...

Phase III results positive for Cymraza + erlotinib in first line NSCLC/EGFR

 Added 8 days ago

Eli Lilly and Company announced that its Phase III RELAY study of Cymraza (ramucirumab) met its primary endpoint of progression-free...

European Commission approves Tecentriq + Avastin and chemotherapy for the initial treatment of specific types of metastatic lung cancer

 Added 12 days ago

Roche has announced that the European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab) in combination with Avastin...

European Commission approves Zirabev (bevacizumab biosimilar)to treat the same indications as the originator product. Avastin. - Pfizer

 Added 27 days ago

Pfizer Inc. announced the European Commission (EC) has approved Zirabev for the treatment of metastatic carcinoma of the colon or...

FDA accepts sBLA for Keytruda to treat advanced small cell lung cancer. - Merck Inc.,

 Added 1 month ago

Merck Inc., announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA)...

CHMP extends label for Keytruda plus carboplatin and either paclitaxel or nab-paclitaxel to treat NSCLC. Merck Inc.

 Added 1 month ago

On 31 January 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to...

FDA approves Alimta + Keytruda for NSCLC with no EGFR /ALK mutations.- Eli Lilly

 Added 1 month ago

Eli Lilly and Company announced that the FDA has granted approval for a new indication for Alimta (pemetrexed for injection)...

FDA expands label of Alimta + Keytruda for the first-line treatment of metastatic nonsquamous NSCLC.- Eli Lilly + Merck inc.

 Added 1 month ago

Eli Lilly and Company announced that the FDA has granted approval for a new indication for Alimta (pemetrexed for injection)...

BMS withdraws sBLA for Opdivo + Yervoy (low dose) for NSCLC patients with tumor mutational burden.

 Added 1 month ago

Following recent discussions with the FDA, BMS announced the voluntary withdrawal of the U.S. supplemental Biologics License Application (sBLA) for...

Load more